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Tissue Matrix Analysis -One cartilage tissue sample at the time of surgery, and one cartilage explant from each animal in each test group were collected on days 3, 12, and 30 of culture and analyzed for total sulfated GAG via DMMB assay, total collagen content via hydroxyproline (HP) measurement and cartilage DNA content using the picogreen DNA stain.
2
Media analysis -GAG content was measured as previously described. Concentrations of chondroitin sulfate 846 (CS-846) were measured via immunoassay (IBEX), while Nitric oxide (NO) levels were measured by Griess assay (Promega), and PGE2 (pg/ml) by ELISA (Cayman). MMP-2,-3, and -13 were measured by multiplex luminex assay (R&D Systems).Tissue gene expression -RNA extraction and gene expression analysis for matrix molecules (Aggrecan and Collagen II), proteinases (MMP-1, MMP-2, MMP-3, MMP-9, MMP-13, aggrecanase-1, and aggrecanase-2), proteinase inhibitors (tissue inhibitors of metalloproteinase (TIMP-1, TIMP-2, and TIMP-3), inflammatory indicators (IL-1β, TNF-α, COX-1, COX-2 and INOS), and the house keeping gene (GAPDH) were measured by real time reverse transcription polymerase chain reaction (RT-PCR). Total RNA was extracted from the cartilage explant using the Trispin method, and RNA was converted to cDNA using the superscript III enzyme as previously described.
Statistical Analysis -For comparisons between group 1 subgroups (Cm:control) and (Mm 0.3 , Mm 3.0 , and Mm 30.0 ) where subgroups included the same dogs, a repeated measures model was used to test for differences between gene expression, tissue and media measurements between groups and days. Multiple comparisons were adjusted for using Tukey's test. For comparisons between MPM:Cm, and Cm:control where each group included different dogs, an analysis of variance (ANOVA) test was used. Multiple comparisons were adjusted using Tukey's test. Significance level was set at α = 0.05.
RESULTS:
Cartilage matrix analysis revealed that meloxicam had no effect on GAG, HP or DNA content compared between Cm:control, Mm 0.3 , Mm 3.0 , and Mm 30.0 subgroups at any time point.
Media analysis revealed lower PGE2 on day 3 concentrations in all three meloxicam treated subgroups compared to Cm:control. Media NO levels showed no difference between days 3, 12 or 30, within or between Cm:control, Mm 0.3 , Mm 3.0 , and Mm 30.0 subgroups. GAG release decreased significantly in all group1 subgroups on days 12 and 30 compared to day3. Media CS-846 showed a significant decrease between day 3 and days 12 and 30 in the Cm:control subgroup. Meloxicam treated subgroups had no change between any time points in CS-846. There was significantly more CS-846 released at day 3 in the Cm:control media subgroup when compared to all three meloxicam treated subgroups. Media levels of MMP-2, and MMP-13 were not different within or between Cm:control, Mm 0.3 , Mm 3.0 , and Mm 30.0 subgroups. MMP-3 production was significantly decreased in Mm 0.3 , Mm 3.0 and Mm 30.0 subgroups between Days 3 and 30. Chondrocyte aggrecan gene expression was significantly greater on days 12 and 30 compared to day 0 for the Cm:control group. None of the meloxicam treated explants showed increased aggrecan gene expression over the study period. Aggrecanase-2 gene expression significantly decreased in all group 1 subgroups on all days compared to baseline. TIMP-2 gene expression was significantly increased at day 30 compared to day 0 in the Cm:control subgroup. None of the meloxicam treated subgroups showed changes in TIMP-2 gene expression over the study period. INOS gene expression significantly decreased in all group 1 subgroups on all days compared to day 0.
Ex-vivo meloxciam pretreated cartilage showed no differences within or between MPM:cm and Cm:control groups in GAG, HP or DNA content at any time point. CS-846 levels were significantly greater in the Cm:control group compared to MPM:cm on day 3. Cm:control levels of CS-846 decreased significantly by day 12 compared to day 3. Media MMP-3 concentrations were significantly less on days 12 and 30 compared to day 3 in the MPM:cm group. No differences in MMP-3 levels were seen between groups. Media MMP-13 was significantly greater in the MPM:cm compared to Cm:control on days 3 and 12. There was significantly more NO in the MPM:cm media on day 3 compared to Cm:control. Media PGE-2 levels significantly decreased from day 3 to day 30 in both groups with no differences between groups. Cm:control Collagen-2 gene expression was significantly greater than MPM:cm on day 3. Cm:control MMP2 gene expression significantly increased on days 3, 12, and 30 compared to day 0. MPM:cm group MMP-2 gene expression was significantly lower than Cm:control on days 3 and 12. COX-2 gene expression was significantly greater on day 3 compared to day 30 in the MPM:cm group. TNF-α gene expression was significantly greater in the MPM:cm group compared to Cm:control on day 12.
DISCUSSION:
Interestingly these data suggest that meloxicam treatment of naturally occurring OA cartilage did not induce degradation over 30 days of treatment and in some measures (media CS-846 and MMP-3) appeared to prevent degradation at concentrations up to 100 times the expected synovial concentrations. It is not surprising that measures of synthesis did not increase as growth simulating factors were not included in this study. Furthermore, meloxicam effectively decreased inflammatory mediator production (PGE2) in OA chondrocytes. Meloxicam also appeared to stop the upregulation of certain degradative genes including Aggrecan and TIMP-2, which again suggests sparing of the OA cartilage during drug therapy. Ex-vivo pretreatment of OA cartilage with meloxicam did not appear to induce degradative processes in the cartilage as the cartilage was evaluated for 30 days following removal of drug. Pretreated cartilage did show less loss of CS-846 in the media than control cartilage over the study period as well as less expression of the Collagen-2 gene expression compared to the Cm:control group on day 3. Muting the upregulation of degradative genes with ex-vivo pretreatment was less consistent. 
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